Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Join | Sign in
Home>Videos>This Video
  Videos

Return

Preclinical Drug Safety: High Quality Data obtained with a New Automated Patch Clamp Platform
Select Biosciences Ltd

Many compounds have been reported to prolong the QT interval interfering with the hERG channel, leading to life-threatening cardiac arrhythmias. According to FDA guideline every drug going to market must be tested on the hERG channel. Due to this international regulation, there is a great demand for accurate hERG screens as well as for other pacemaker channels. Manual patch clamp is still the gold standard for investigation of ion channels, but throughput is low and a skilled operator is needed. Cytocentrics overcomes these problems by developing the CytoPatch™ Instrument. Thus outsourcing of patch clamp screening offers a true advantage to drug developing companies: Lowering their operating costs and having access to the latest technology and scientific expertise. As examples for the patch clamp quality of the CytoPatch™ Instrument we show that the electrophysiological and pharmacological properties of the cardiac potassium channels like hERG and kv1.5 investigated on the CytoPatch™ Instrument are in excellent agreement with data known from manual patch clamp: This demonstrates that ion channel screening on the CytoPatch™ Instrument delivers the same high data quality known from manual patch clamp at a throughput level required for safety pharmacology screening.

Request more information
Company product page


Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Human Trials of Manufactured Blood Within Two Years
The first human trials of lab-produced blood to help create better-matched blood for patients with complex blood conditions has been announced by NHS Blood and Transplant.
New Medication for Alcohol Use Disorder
NIH begins clinical trial investigating a potential treatment for alcohol use disorder.
Behavior Matters: Redesigning the Clinical Trial
A recent meta-analysis of six such clinical trials shows that behavior can have a serious impact on the effectiveness of a treatment and that the currently used DBRCT procedures may not be able to assess the effects of behavior on the treatment.
New Commercial Method for Producing Medical Isotope
The effort to secure a stable, domestic source of a critical medical isotope reached an important milestone this month as scientists demonstrated the production, separation and purification of molybdenum-99 (Mo-99.
NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities
Precision medicine trial will open to patient enrollment in July.
Linking Targeted Cancer Drugs to Gene Abnormalities
Investigators at the NIH have announced a series of clinical trials that will study drugs or drug combinations that target specific genetic mutations.
IAOCR Welcomes Important Initial Step for Regulating European Clinical Trials
New regulation to ensure a more streamlined risk-based approach to the conduct of trials with more public openness about each trial and the results they produce.
Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals
NIH-funded trial results likely will impact global treatment guidelines.
Amgen Terminates Co-Development of Brodalumab with AstraZeneca
This move follows the release of clinical trial data which suggests the experimental drug has severe side effects.
Baylor, TGen Collaborate on Personalized Cancer Treatment Options
The companies will collaborate on precision medicine for cancer patients by offering liquid biopsies, performing gene sequencing, conducting clinical trials, and creating personalized vaccines.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters